📈 Live Market Tracking
Every NSE and BSE corporate filing, read and explained by AI within minutes — impact, key figures, short/long-term view and what to watch.
Live · AI analyzer runs every 5 min (07:00–23:55 IST)
Latest filing: 2026-08-17 16:59
690 analysed today
690
Today
133,579
All-time analysed
40,122
Positive
6,284
Negative
79,354
Neutral
7,751
Watch
📊 Last 7 days — analysed filings by sentiment
Note: These are AI-generated, educational summaries of public NSE
filings — grounded in each document, but not investment advice and possibly incomplete.
Verify against the original filing and consult a SEBI-registered adviser before acting.
19 announcements match the current filters (relevance ≥ 5).
Suraksha Diagnostic Q1 FY27 Transcript: Revenue Up 21% YoY, PAT Jumps 40% to ₹12.8 Cr
Suraksha Diagnostic released its Q1 FY27 earnings call transcript, reporting a 21% YoY rise in total income to INR 88.7 cr and a 40% YoY jump in PAT to INR 12.8 cr. Network count reached 72 centres, with immature centres (<2 years old) turning EBITDA positive at 6.5% versus -5.5% in the prior quarter. The company is actively expanding beyond West Bengal into Jharkhand and Tripura, with plans to add ~20 labs in FY27. Specialized testing arm Suraksha Genomics grew 136% YoY to INR 1.37 cr, marking five consecutive quarters of sequential growth.
Confidence: HIGH
What changedSuraksha Diagnostic published the transcript of its Q1 FY27 earnings call detailing regional expansion plans and margin drivers.
Why it mattersShows operational leverage playing out as younger centres turn profitable and regional diversification beyond West Bengal gains traction.
Q1 FY27 Revenue: INR 88.7 crQ1 FY27 PAT: INR 12.8 crPAT Growth (YoY): 40%EBITDA Margin: 36%Total Centres: 72Genomics Revenue: INR 1.37 cr
📅 Short termStrong operational momentum and profitability in young centers support stable near-term performance.
📈 Long termGeographic diversification across Eastern and Northeastern India and scale in high-value genomics panels could drive sustained margin expansion.
⚠ Risk flags
- Moderation in test volume growth pace to 10-11% compared to >20% in preceding quarters
- Execution and brand acceptance risks in newly entered non-core geographies like Jharkhand and Tripura
Key Highlights
Q1 FY27 total income grew 21% YoY to INR 88.7 cr (INR 887 mn) with EBITDA margin expanding to 36% from 34%.
Net profit surged 40% YoY to INR 12.8 cr (INR 128 mn) with PAT margin reaching 14.7%.
Total centres reached 72 at quarter-end; immature centres turned EBITDA positive at 6.5% margin.
Suraksha Genomics revenue surged 136% YoY to INR 1.37 cr (INR 13.7 mn).
Expansion beyond West Bengal began with a commissioned hub in Jharkhand and an upcoming hub in Tripura.
👀 What to Watch
Track the execution and utilization ramp-up of new centres in Jharkhand and Tripura, alongside monitoring volume growth trends in routine pathology.
40% PAT Growth in Q1 FY27; Suraksha Diagnostic Reports Margin Expansion to 36%
Suraksha Diagnostic reported a strong start to FY27 with total income rising 21% YoY to ₹88.7 Cr. Profitability significantly outperformed revenue growth, with PAT increasing 40% to ₹12.8 Cr and EBITDA margins expanding by 200 bps to 36.0%. Operational efficiency improved as Average Revenue per Patient (ARPP) grew 10.5% to ₹2,321, despite a slight 2.8% dip in tests per patient. The company continued its expansion by adding 1 hub and 3 spoke centers during the quarter.
Confidence: HIGH
What changedThe company achieved a significant margin expansion and strong bottom-line growth, driven by higher realizations per patient and rapid growth in specialized genomics testing.
Why it mattersThe results demonstrate the company's ability to improve profitability through a better product mix (Genomics) and higher realizations, even while continuing its physical network expansion in Eastern India.
Q1 FY27 Total Income: ₹887 millionQ1 Revenue vs TTM Revenue: ~28.6%EBITDA Margin: 36.0%PAT Growth (YoY): 40.0%Genomics Revenue Growth: 136%Average Revenue per Patient: ₹2,321
📅 Short termThe stock may react positively to the strong margin expansion and 40% PAT growth, which exceeds the TTM growth trajectory.
📈 Long termStructural growth remains tied to the successful ramp-up of 12-15 new centers annually and the transition towards high-margin specialized diagnostics like Genomics and prenatal care.
⚠ Risk flags
- Intense competition in West Bengal from pan-India diagnostic players
- Potential impact of seasonal weather/floods on patient mobility in Eastern India
Key Highlights
Profit After Tax (PAT) grew 40% YoY to ₹128 million (₹12.8 Cr) in Q1 FY27.
EBITDA margins improved to 36.0% from 34.0% in the corresponding quarter last year.
Suraksha Genomics segment delivered a robust revenue growth of 136% YoY.
Average Revenue per Patient (ARPP) increased by 10.5% to ₹2,321.
Network expansion continued with the commissioning of 1 hub and 3 spoke centers in Q1 FY27.
👀 What to Watch
Investors should monitor the margin sustainability as the company scales its 15 immature centers and tracks the revenue contribution from the high-margin Genomics segment.
40% PAT Growth in Q1 FY27; Revenue up 21% to ₹87.65 Cr with 36% EBITDA Margin
Suraksha Diagnostic reported a strong start to FY27 with Q1 revenue growing 21% YoY to ₹87.65 Cr and PAT surging 40% to ₹12.85 Cr. Operating margins (EBITDA) expanded to 36.0% from 34.0% YoY, driven by a high B2C revenue mix of 91% and increased revenue per patient of ₹2,321. The company is aggressively expanding its footprint, adding 4 centers in Q1 and entering new markets in Jharkhand and Tripura. A key profitability driver is the maturation of centers; mature centers (>2 years) operate at a 40.9% EBITDA margin compared to just 6.5% for newer centers.
Confidence: HIGH
What changedThe company has successfully expanded its EBITDA margins by 200 bps YoY and begun geographic diversification into Jharkhand and Tripura to reduce West Bengal concentration.
Why it mattersThe strong Q1 performance validates the company's ability to maintain high margins (36%) while scaling. The 40% PAT growth on a 21% revenue increase indicates significant operating leverage as newer centers begin to break even.
Q1 FY27 Revenue: ₹87.65 CrQ1 Revenue vs TTM Revenue: ~28.3%EBITDA Margin: 36.0%B2C Revenue Mix: 91%Mature Center EBITDA Margin: 40.9%New Center EBITDA Margin: 6.5%
📅 Short termThe stock is likely to react positively to the 40% PAT growth and the significant margin expansion reported for the quarter.
📈 Long termStructural growth is supported by the expansion into neighboring states (Jharkhand, Tripura) and the high-margin Genomics segment, which is scaling rapidly from a small base.
⚠ Risk flags
🔬 Flagged for deeper Multibagger analysis — view briefs →
- High geographic concentration (96% revenue from West Bengal)
- Intense competition from pan-India diagnostic players
- Execution risk in new territories
Key Highlights
Revenue from operations increased 21% YoY to ₹876.5 Mn, while PAT grew 40% YoY to ₹128.5 Mn.
EBITDA margins reached 36.0%, with mature centers (>2 years) achieving a high margin of 40.9%.
Network expanded to 72 centers as of June 2026, with 9 additional centers (3 hubs, 6 spokes) already launched or planned for FY27.
Suraksha Genomics revenue grew 136% YoY to ₹13.7 Mn, marking five consecutive quarters of sequential growth.
Revenue per patient improved to ₹2,321 in Q1 FY27 from ₹2,101 in Q1 FY26.
👀 What to Watch
Investors should monitor the ramp-up of the 27 'immature' centers (less than 2 years old), as their transition toward the 40.9% margin profile of mature centers is the primary catalyst for earnings growth.
Suraksha Diagnostic Sets Sept 15 Dividend Record Date; Appoints New Group CFO
Suraksha Diagnostic reported standalone revenue of ₹84.09 Cr for Q1 FY27, representing a sequential growth of 6.7% over the March 2026 quarter. The board has fixed September 15, 2026, as the record date for the FY26 dividend, with the AGM scheduled for September 22. Additionally, Mr. Dinesh Gupta has been appointed as the Group Chief Financial Officer effective August 24, 2026. The company maintained a standalone net profit of ₹12.58 Cr for the quarter ended June 30, 2026.
Confidence: HIGH
What changedThe company has finalized its Q1 FY27 financial results, scheduled its annual shareholder meeting, and transitioned its financial leadership with a new CFO appointment.
Why it mattersThe appointment of a new CFO is significant as the company executes its 15% growth strategy and expansion into high-margin segments like genomics. The Q1 results indicate steady revenue momentum relative to the TTM average.
Q1 FY27 Standalone Revenue: ₹84.09 CrQ1 FY27 Standalone PAT: ₹12.58 CrDividend Record Date: 15-Sep-2026CFO Appointment Date: 24-Aug-2026Q1 Revenue vs TTM Revenue: 27.1%
📅 Short termThe stock may see routine activity around the dividend record date and the market's assessment of the Q1 earnings performance.
📈 Long termLong-term value depends on the successful scaling of the 33% currently immature centers and the integration of the Fetomat acquisition to boost margins.
⚠ Risk flags
- Management transition risk (New CFO)
- Intense competition in West Bengal pathology market
- Dependency on reagent suppliers
Key Highlights
Standalone Revenue for Q1 FY27 stood at ₹84.09 Cr, up from ₹78.79 Cr in the previous quarter
Standalone Net Profit for the quarter ended June 30, 2026, reported at ₹12.58 Cr
Record date for FY26 dividend entitlement fixed for September 15, 2026
Appointment of Mr. Dinesh Gupta as Group CFO effective August 24, 2026
21st Annual General Meeting (AGM) to be held on September 22, 2026
👀 What to Watch
Investors should track the transition to the new CFO and monitor the upcoming AGM for updates on the company's plan to add 12-15 new centers in FY26.
Suraksha Diagnostic Appoints Dinesh Gupta as CFO; Q1 FY27 PAT Rises 37% to ₹12.58 Cr
Suraksha Diagnostic reported a strong start to FY27 with Q1 revenue reaching ₹84.08 Cr, a 15.8% increase over the ₹72.59 Cr reported in Q1 FY26. Net profit for the quarter surged 37% YoY to ₹12.58 Cr, driven by improved operational efficiencies. The board has appointed Mr. Dinesh Gupta, a Chartered Accountant with 14 years of experience, as the new Group CFO effective August 24, 2026. Additionally, the company fixed September 15, 2026, as the record date for the FY26 dividend payment.
Confidence: HIGH
What changedThe company has transitioned its financial leadership to Mr. Dinesh Gupta and reported double-digit growth in both top-line and bottom-line for the first quarter of FY27.
Why it mattersStrong Q1 results validate the company's 15% growth target and its ability to scale in the competitive Eastern India market. The appointment of a seasoned CFO is critical for managing the planned 30% increase in store count.
Q1 FY27 Revenue: ₹84.08 CrQ1 FY27 PAT: ₹12.58 CrYoY PAT Growth: 37.1%CFO Experience: 14 yearsDividend Record Date: September 15, 2026
📅 Short termThe stock may see positive momentum following the 37% PAT growth and the announcement of the dividend record date.
📈 Long termThe company's focus on high-margin segments like Genomics and its aggressive center expansion (12-15 annually) remain the primary structural growth drivers.
⚠ Risk flags
- Intense competition in West Bengal from pan-India diagnostic chains
- Execution risk in scaling 15 centers that are currently less than one year old
Key Highlights
Q1 FY27 Revenue grew 15.8% YoY to ₹84.08 Cr from ₹72.59 Cr
Net Profit for the quarter increased 37.1% YoY to ₹12.58 Cr
Appointment of Mr. Dinesh Gupta as Group CFO effective August 24, 2026
Record date for FY26 dividend set for September 15, 2026
Profit Before Tax (PBT) stood at ₹16.71 Cr for the quarter ended June 2026
👀 What to Watch
Watch for the new CFO's impact on cost management as the company executes its plan to add 12-15 new centers in FY27. Investors should also note the dividend record date of September 15 for entitlement.
Suraksha Diagnostic Q1 PAT Rises 37% YoY to ₹12.58 Cr; Appoints New Group CFO
Suraksha Diagnostic reported a strong start to FY27 with standalone revenue growing 15.8% YoY to ₹84.09 cr. Net profit saw a significant jump of 37% YoY to ₹12.58 cr, compared to ₹9.18 cr in the year-ago period. The company also announced the appointment of Mr. Dinesh Gupta as Group CFO, effective August 24, 2026, and fixed September 15, 2026, as the record date for the FY26 dividend. These results indicate the company is tracking well against its 15% annual growth guidance.
Confidence: HIGH
What changedThe company reported its Q1 FY27 financial performance and transitioned to a new Group CFO.
Why it mattersThe strong earnings growth validates the company's leadership in Eastern India and its ability to scale margins despite competition; the CFO appointment ensures management continuity for expansion plans.
Q1 Standalone Revenue: ₹84.09 crQ1 Standalone PAT: ₹12.58 crYoY Revenue Growth: 15.8%YoY PAT Growth: 37.0%Dividend Record Date: 15 September 2026
📅 Short termThe stock may see positive sentiment in the coming days due to the strong YoY profit growth and the upcoming dividend record date.
📈 Long termThe company's strategy to add 12-15 centers annually and scale high-margin segments like genomics remains the primary long-term value driver.
⚠ Risk flags
- Intense competition in West Bengal from pan-India diagnostic players
- Dependency on reagent suppliers and timely sample transport
Key Highlights
Standalone Revenue from operations increased 15.8% YoY to ₹84.09 cr in Q1 FY27.
Standalone Net Profit grew 37% YoY to ₹12.58 cr, up from ₹9.18 cr in Q1 FY26.
Earnings Per Share (EPS) improved to ₹2.42 from ₹1.80 in the corresponding quarter last year.
Record date for the FY26 dividend is fixed for September 15, 2026.
Appointment of Mr. Dinesh Gupta as Group CFO, bringing 14 years of finance experience from firms like Genpact and Maersk.
👀 What to Watch
Investors should monitor the execution of the planned 12-15 new center additions for FY26 and the impact of the new CFO on strategic cost management and margin expansion.
Suraksha Diagnostic Q1 Revenue Grows 15.8% YoY to ₹84.09 Cr; Appoints New Group CFO
Suraksha Diagnostic reported a standalone revenue of ₹84.09 Cr for Q1 FY27, a 15.8% increase over the ₹72.59 Cr reported in Q1 FY26. Standalone net profit for the quarter rose to ₹12.58 Cr, compared to ₹9.18 Cr in the year-ago period, reflecting strong bottom-line growth. The board also appointed Mr. Dinesh Gupta as the new Group CFO, effective August 24, 2026, to lead financial strategy. Additionally, the company fixed September 15, 2026, as the record date for the FY26 dividend payment.
Confidence: HIGH
What changedThe company reported its first-quarter results for FY27 and announced a transition in its top financial leadership with a new Group CFO.
Why it mattersThe double-digit revenue growth confirms the company is meeting its 15% growth guidance, while the profit growth suggests improving operational leverage in the competitive Eastern India market.
Q1 FY27 Revenue (Standalone): ₹84.09 CrYoY Revenue Growth: 15.8%Q1 FY27 Net Profit (Standalone): ₹12.58 CrCFO Experience: 14 yearsDividend Record Date: 15 September 2026
📅 Short termThe stock may see positive sentiment in the coming days due to the healthy YoY growth in both revenue and profitability.
📈 Long termThe company's focus on high-margin segments like Genomics and its expansion strategy in West Bengal remain key structural drivers for long-term value.
⚠ Risk flags
- Intense competition in West Bengal from pan-India diagnostic players
- Dependency on reagent suppliers for pathology services
Key Highlights
Standalone revenue for Q1 FY27 reached ₹84.09 Cr, up 15.8% from ₹72.59 Cr in Q1 FY26.
Standalone net profit increased to ₹12.58 Cr from ₹9.18 Cr in the corresponding quarter of the previous year.
Appointment of Mr. Dinesh Gupta as Group CFO, a seasoned professional with over 14 years of experience.
Record date for the FY26 dividend set for September 15, 2026, with the AGM scheduled for September 22, 2026.
Total standalone expenses for the quarter stood at ₹69.10 Cr, with material costs accounting for ₹11.85 Cr.
👀 What to Watch
Investors should monitor the new CFO's impact on cost management and the execution of the planned 12-15 new center additions for FY26 to sustain this growth momentum.
Suraksha Diagnostic FY26 Revenue Up 23% to ₹310 Cr; EBITDA Margins Steady at 31.7%
Suraksha Diagnostic Limited reported a robust 23.1% YoY increase in FY26 revenue to INR 3,104.1 million, driven by higher volumes and a premium test mix. EBITDA margins remained strong at 31.73%, although full-year PAT growth was limited to 1.4% at INR 314 million due to increased depreciation and finance costs from network expansion. The company expanded its footprint to 68 centers and plans to enter Bihar, Jharkhand, and Tripura in FY27. Revenue per patient improved to INR 2,264, reflecting a strategic shift toward high-end radiology and genomics.
Key Highlights
FY26 Revenue grew 23.1% YoY to INR 3,104.1 million with a 3-year CAGR of 17.78%.
EBITDA margin for the year stood at 31.73%, while mature centers achieved 36-37%.
Total patient count reached 1.37 million with a significant volume of 8.16 million tests.
Network expanded to 68 centers, with plans to add 3 hubs and 8 spokes in West Bengal in FY27.
Revenue per patient increased to INR 2,264, supported by advanced radiology and genomics.
👀 What to Watch
Investors should monitor the margin trajectory as new centers in Bihar and Jharkhand scale up. The company's strong presence in Eastern India and high-end diagnostic capabilities provide a solid long-term growth outlook.
Suraksha Diagnostic FY26 Income up 23% to ₹3,136M; Q4 EBITDA Grows 26% YoY
Suraksha Diagnostic reported a robust 23% YoY growth in total income for FY26, reaching ₹3,136 million, supported by a 22% increase in test volumes. While full-year PAT remained nearly flat at ₹314 million (+1.4%) due to aggressive expansion costs, Q4 FY26 showed strong operational momentum with EBITDA rising 25.7% YoY. The company added 17 new facilities (hubs, spokes, and PPPs) during the year, which temporarily compressed margins. Management noted that mature centers (over 2 years old) maintain high EBITDA margins of 36-37%, indicating significant upside as new centers scale.
Key Highlights
Total Income for FY26 increased by 23% YoY to ₹3,136 million, with Q4 FY26 income up 24.7% to ₹822 million.
FY26 EBITDA grew 16% YoY to ₹986 million, though Q4 FY26 EBITDA showed a stronger growth of 25.7% YoY.
Total test volumes grew 22% YoY in FY26 to 8.16 million, while Q4 Average Revenue Per Patient (ARPP) surged 23% to ₹2,706.
Network expansion included the addition of 2 hubs, 11 spoke centres, and 4 PPP projects during the financial year.
Mature centers (>2 years old) are operating at stable EBITDA margins of 36-37%.
👀 What to Watch
Investors should focus on the volume growth and the scaling of the 17 newly added centers, as their maturation is the primary catalyst for margin expansion. The stock remains a growth play in the East Indian diagnostic market, with the current PAT compression being a result of strategic long-term capacity building.
Suraksha Diagnostic FY26 Revenue Grows 23% to ₹3,136M; Network Expands to 68 Centres
Suraksha Diagnostic Limited reported a robust 23% YoY revenue growth for FY26, reaching ₹3,136 million, driven by volume growth and network expansion in Eastern India. While EBITDA grew 16% to ₹986 million, PAT remained nearly flat at ₹314 million due to higher depreciation and finance costs associated with adding 20 new centres since listing. A key highlight is the performance gap between mature centres (36.5% EBITDA margin) and newer centres (-5.5% EBITDA margin), indicating significant margin expansion potential as the new units scale up.
Key Highlights
FY26 Revenue increased 23% YoY to ₹3,136 million, with Q4 FY26 revenue up 25% to ₹822 million.
EBITDA for FY26 stood at ₹986 million with a 31.8% margin, though Q4 margins improved to 30.9% compared to the previous quarter.
The company served 1.37 million patients and performed 8.16 million tests in FY26, with a high B2C revenue contribution of 89%.
Network expanded to 68 diagnostic centres and 193 collection centres, with 20 centres added since the December 2024 listing.
Mature centres (>2 years old) maintained strong profitability with EBITDA margins between 36-37%.
👀 What to Watch
Investors should focus on the 'maturation curve' of the 26 new centres; as these transition from -5.5% to the company's mature 36% margin profile, earnings are expected to accelerate. The stock remains a strong regional play in the Eastern Indian diagnostic market with high B2C stickiness.
Suraksha Diagnostic FY26 Revenue Grows 20.7% to ₹300.7 Cr; Recommends ₹0.50 Dividend
Suraksha Diagnostic reported a strong performance for FY26, with annual revenue from operations increasing by 20.7% to ₹30,067.91 lakhs compared to the previous year. The Board has recommended a final dividend of ₹0.50 per equity share (25% of face value) for the financial year. For the quarter ended March 31, 2026, revenue stood at ₹7,855.59 lakhs, showing healthy year-on-year growth from ₹6,414.51 lakhs. The company also announced the appointment of new internal auditors and fixed August 26, 2026, as the record date for the dividend.
Key Highlights
Annual revenue from operations grew 20.7% YoY to ₹30,067.91 lakhs in FY26
Q4 FY26 revenue increased to ₹7,855.59 lakhs from ₹6,414.51 lakhs in the same quarter last year
Recommended a final dividend of ₹0.50 per share (25% on face value of ₹2)
Total income for FY26 reached ₹30,503.14 lakhs compared to ₹25,347.84 lakhs in FY25
Record date for dividend entitlement set for August 26, 2026
👀 What to Watch
Investors should note the steady double-digit revenue growth and the consistent dividend payout. The stock remains a key player to watch within the diagnostic sector, particularly for its regional dominance in Eastern India.
Suraksha Diagnostic FY26 Revenue Grows 20.7% to ₹300.68 Cr; Recommends ₹0.50 Dividend
Suraksha Diagnostic Limited reported a robust financial performance for the fiscal year ended March 31, 2026, with annual revenue from operations rising 20.7% to ₹30,067.91 lakhs from ₹24,909.54 lakhs in the previous year. The fourth quarter also showed strong momentum, with revenue reaching ₹7,855.59 lakhs, a 22.5% increase year-on-year. Consequently, the Board has recommended a final dividend of ₹0.50 per equity share (25% of face value). The company also announced the appointment of new internal auditors and the schedule for its 21st Annual General Meeting.
Key Highlights
Annual revenue from operations increased by 20.7% YoY to ₹30,067.91 lakhs in FY26.
Q4 FY26 revenue stood at ₹7,855.59 lakhs compared to ₹6,414.51 lakhs in Q4 FY25.
Recommended a final dividend of ₹0.50 per equity share of face value ₹2 each.
Fixed August 26, 2026, as the Record Date for dividend entitlement.
Appointed M/s. Suresh Surana & Associates LLP as Internal Auditor for FY 2026-27.
👀 What to Watch
Investors should monitor the company's ability to maintain this 20%+ growth rate in a competitive diagnostic market. The dividend provides a modest yield, and the record date of August 26 is the key date for eligibility.
Suraksha Diagnostic Declares ₹0.50 Final Dividend; FY26 Revenue Up 20.7% YoY
Suraksha Diagnostic Limited has recommended a final dividend of ₹0.50 per equity share (25% of face value) for the financial year 2025-26. The company reported a strong standalone performance with annual revenue from operations rising to ₹300.68 crore in FY26, up from ₹249.10 crore in the previous fiscal year. Quarterly revenue for Q4 FY26 also showed robust growth, reaching ₹78.56 crore compared to ₹64.15 crore in Q4 FY25. The board has fixed August 26, 2026, as the record date for dividend eligibility.
Key Highlights
Recommended a final dividend of ₹0.50 per equity share of face value ₹2 (25%).
Standalone annual revenue from operations grew 20.7% YoY to ₹30,067.91 lakhs.
Q4 FY26 revenue increased to ₹7,855.59 lakhs from ₹6,414.51 lakhs in the previous year's quarter.
Record date for dividend entitlement is fixed as August 26, 2026.
Total annual income for FY26 reached ₹30,503.14 lakhs compared to ₹25,347.84 lakhs in FY25.
👀 What to Watch
Investors should maintain their positions to benefit from the upcoming dividend payout and monitor the company's ability to sustain this 20%+ revenue growth rate.
Suraksha Diagnostic FY26 Revenue Jumps 20.7% to ₹300.68 Cr; Recommends ₹0.50 Dividend
Suraksha Diagnostic Limited reported a strong financial performance for the fiscal year ended March 31, 2026, with annual revenue from operations growing 20.7% YoY to ₹30,067.91 lakhs. The fourth quarter also showed robust growth, with revenue reaching ₹7,855.59 lakhs, a 22.5% increase over the corresponding quarter last year. In addition to the growth, the board has recommended a final dividend of ₹0.50 per equity share (25% of face value). The company has also finalized its 21st AGM for September 2, 2026, and appointed new internal auditors for the next fiscal year.
Key Highlights
Annual revenue from operations increased by 20.7% YoY to ₹30,067.91 lakhs in FY26.
Q4 FY26 revenue grew 22.5% YoY to ₹7,855.59 lakhs compared to ₹6,414.51 lakhs in Q4 FY25.
Recommended a final dividend of ₹0.50 per equity share of face value ₹2 (25% payout).
Total income for the full financial year FY26 reached ₹30,503.14 lakhs.
Record date for dividend entitlement is fixed as August 26, 2026.
👀 What to Watch
Investors should take note of the consistent double-digit revenue growth and the dividend payout; the stock remains a 'Hold' with a positive bias toward long-term expansion in the diagnostic sector.
Suraksha Diagnostic Group CFO K S Ravindra Resigns Effective May 31, 2026
Suraksha Diagnostic Limited has announced the resignation of Mr. K S Ravindra from the post of Group Chief Financial Officer (CFO) and Key Managerial Personnel (KMP). The resignation was tendered on March 2, 2026, citing personal reasons, with his tenure concluding on May 31, 2026. The company has initiated a three-month notice period to ensure a smooth transition of financial responsibilities. No material reasons other than personal ones were cited for the departure.
Key Highlights
Mr. K S Ravindra resigned as Group CFO and KMP on March 2, 2026
The resignation is effective from the close of business hours on May 31, 2026
A 3-month notice period is being served to facilitate a smooth leadership transition
The outgoing CFO confirmed there are no material reasons for resignation other than personal ones
👀 What to Watch
Investors should monitor the company's upcoming announcements regarding the appointment of a new CFO to ensure continuity in financial management. The three-month notice period provides a reasonable window for a stable transition.
Suraksha Diagnostic Q3 Revenue Jumps 30% YoY to ₹78.3 Cr; EBITDA Margins at 30.6%
Suraksha Diagnostic reported a strong 30.3% YoY increase in Q3 FY26 revenue to INR 783.09 million, driven by volume expansion and a shift towards high-value genomic testing. While EBITDA grew 26.1% to INR 237.82 million, margins saw a temporary compression to 30.6% due to pre-operative costs associated with 24 new centers. The company served 0.36 million patients in Q3, a 23% increase, while the total number of tests performed rose by 30.7% to 2.06 million. Management revised EBITDA margin guidance slightly downward to approximately 32% for the full year, citing aggressive network expansion and seasonal weakness.
Key Highlights
Q3 FY26 revenue grew 30.3% YoY to INR 783.09 million, with 9M FY26 revenue up 21.86% to INR 2,313.81 million
EBITDA margin for Q3 stood at 30.6%, impacted by 24 new centers, while 42 mature centers maintain robust profiles
The new genomics vertical Suraksha Sutra is generating a monthly revenue run rate of approximately INR 2.1-2.2 million
The company remains net debt positive with a cash position of approximately INR 29 crores as of the reporting date
Expansion continues with 12 centers commissioned in 9 months and 6 more facilities currently in the execution phase
👀 What to Watch
Investors should focus on the successful ramp-up of new centers and the high-margin genomics vertical, which act as long-term growth drivers despite short-term margin compression. Monitor the stabilization of EBITDA margins as the 24 new centers reach maturity over the next 12-18 months.
Suraksha Diagnostic Q3 Revenue Jumps 30% to ₹783 Mn; Mature Center Margins Hit 36.2%
Suraksha Diagnostic reported a robust 30.3% YoY revenue growth in Q3 FY26, reaching ₹783.09 million, driven by aggressive network expansion. While overall EBITDA margins compressed slightly to 30.6% due to pre-operative costs of 24 new centers, mature centers (over 2 years old) continue to deliver strong margins of 36.2%. The company is diversifying into high-value segments like Genomics and Fetal medicine to increase revenue per patient, which rose to ₹2,140. Management remains focused on 'Investing for Scale,' with 6 more centers planned for launch in Q4 FY26.
Key Highlights
Q3 FY26 Revenue increased 30.3% YoY to ₹783.09 million, while PAT grew 21% to ₹72.41 million.
Mature centers (42 units) operate at a 36.2% EBITDA margin, while 24 new centers are currently at -12.5% during their gestation period.
Total network reached 66 diagnostic centers and 173 collection centers as of December 31, 2025.
Revenue per patient improved to ₹2,140 in 9M FY26, supported by the launch of the high-margin Suraksha Genomics vertical.
EBITDA for 9M FY26 stood at ₹734.04 million, representing a 12.8% YoY growth despite heavy investment in expansion.
👀 What to Watch
Investors should monitor the margin trajectory as the 24 recently opened centers mature; their shift toward the 36% margin profile of established centers will be the primary driver for future earnings upgrades. The successful scaling of the specialized Genomics vertical remains a key long-term catalyst for valuation re-rating.
Suraksha Diagnostic Q3 FY26 Income Up 30.3% to ₹783M; Test Volumes Surge 30.7%
Suraksha Diagnostic Limited reported robust Q3 FY26 results with total income rising 30.3% YoY to ₹783.09 million. Net profit increased by 21% to ₹72.41 million, while EBITDA grew 26.1% to ₹237.82 million. The company witnessed significant volume growth with total tests increasing by 30.7% YoY to 2.06 million. Although EBITDA margins compressed slightly to 30.6% due to aggressive expansion, mature centers continue to deliver strong 37% margins.
Key Highlights
Total Income grew 30.3% YoY to ₹783.09 million in Q3 FY26.
EBITDA increased by 26.1% YoY to ₹237.82 million with a 30.6% margin.
Total test volume rose 30.7% YoY to 2.06 million; patients served grew 23% to 0.36 million.
Average Revenue per Patient (ARPP) increased 6.1% YoY to ₹2,181.
Added 12 new centers in 9M FY26 with 6 more currently under development.
👀 What to Watch
The stock remains attractive due to strong volume growth and the high-margin potential of mature centers (37%). Investors should watch for margin recovery as the 12 newly added centers scale up over the next 12-18 months.
Suraksha Diagnostic Q3 FY26 Standalone PAT Rises to ₹9.75 Crore, Income Up 20% YoY
Suraksha Diagnostic Limited reported a steady growth in its standalone operations for the quarter ended December 31, 2025. Total standalone income reached ₹58.30 crore, representing a 20.7% increase compared to the ₹48.29 crore reported in the same quarter last year. Standalone Net Profit for the quarter stood at ₹9.75 crore, while consolidated performance was slightly impacted by losses in subsidiaries totaling ₹0.91 crore. The company is also managing a legal dispute in Meghalaya involving ₹4.35 crore in receivables and investments.
Key Highlights
Standalone Total Income grew 20.7% YoY to ₹58.30 crore from ₹48.29 crore in Q3 FY25.
Standalone Profit After Tax (PAT) for Q3 FY26 stood at ₹9.75 crore with an EPS of ₹1.25.
Consolidated subsidiaries contributed ₹2.83 crore in revenue but reported a net loss of ₹0.91 crore for the quarter.
Nine-month (9M FY26) standalone total income reached ₹163.30 crore compared to ₹143.30 crore in the previous year.
Management is monitoring a ₹4.35 crore dispute regarding a step-down subsidiary's operations in Meghalaya.
👀 What to Watch
The core standalone diagnostic business shows robust double-digit growth and healthy profitability. Investors should monitor the turnaround of loss-making subsidiaries and the resolution of the Meghalaya legal dispute which involves significant receivables.
